In 2020, Civica and 18
Blue Cross Blue Shield plans announced an initiative to lower the cost of certain high-priced generic drugs for consumers at the pharmacy counter. The entity named CivicaScript builds on the mission of Civica to reach consumers directly with quality outpatient generic medicines that are affordable and available. CivicaScript's first product, abiraterone acetate 250 mg, is used to treat prostate cancer. CivicaScript's price for the medication is approximately $3,000 per month less than the average cost for someone with Medicare Part D. In January 2021, Civica Rx announced its plans to build an essential medicines manufacturing facility in Virginia, part of a partnership with Virginia-based Phlow Corp to produce sterile injectable medications used in hospitals for COVID-19 patient care, emergency room and intensive-care unit treatments, surgeries, and to treat other serious conditions. ==References==